Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

Table 3

Local tumor response assessed using RECIST and mRECIST criteria.

Response	RECIST criteria			mRECIST criteria
	1 month	3 months	6 months	1 month	3 months	6 months
CR	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (11.5%)	3 (12.5%)	1 (5.9%)
PR	1 (3.0%)	4 (15.4%)	3 (16.7%)	17 (65.4%)	12 (50.0%)	5 (29.4%)
SD	26 (78.8%)	13 (50.0%)	6 (33.3%)	3 (11.5%)	2 (8.3%)	2 (11.8%)
PD	6 (18.2%)	9 (34.6%)	9 (50.0%)	3 (11.5%)	7 (29.2%)	9 (52.9%)
ORR	1 (3.0%)	4 (15.4%)	3 (16.7%)	20 (76.9%)	15 (62.5%)	6 (35.3%)
DCR	27 (81.8%)	17 (65.4%)	9 (50.0%)	23 (88.5%)	17 (70.8%)	8 (47.1%)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate.